■ CooperVision has entered into definitive agreements to acquire Sauflon Pharmaceuticals Ltd. The transaction is anticipated final before October 31, 2014.

■ The Biotrue ONEday presbyopia lens, from Bausch + Lomb, has received U.S. FDA Clearance. The daily disposable lens features the company’s 3-Zone Progressive design and HyperGel material. The company also announced the availability of Soothe Xtra Protection (XP) eye drops with Restoryl, which replenish the lipid layer of the tear film.

■ Johnson & Johnson Vision Care has launched The Sun & Your Eyes: What You Need to Know pamphlet to assist ECPs in educating patients about UV exposure risk to the eyes. View or download the resource in the Education & Resources section of www.ACUVUEProfessional.com.

■ Optometry Giving Sight (OGS) invites you to participate in the 7th annual World Sight Day Challenge to raise funds to help decrease avoidable blindness. For additional information, visit http://bit.ly/1qqmoAf.

■ Optometry Cares — the AOA Foundation awarded David Gibson (Allergan), Milicent Knight, O.D. (Johnson & Johnson Vision Care), Rick Weisbarth, O.D., F.A.A.O. (Alcon), Ed Greene (The Vision Council), Howard Purcell, O.D., F.A.A.O. (Transitions/Essilor), Joe Mallinger, O.D., M.B.A., F.A.A.O. (Vision West), Dave Sattler (Alcon), Alan Urie (CareCredit) and Joanna Pisani (Luxottica) during the organization’s Major Donor Reception at Optometry’s Meeting in Philadelphia, Pa.

■ The NASA Ocular Health Study, which examined ocular changes in International Space Station astronauts via the Spectralis OCT, received Heidelberg Engineering’s Xtreme Research Award.

■ Nicox announced the launch of RetnaGene AMD and RetnaGene LR (Sequenom Laboratories) genetic tests, which assess an individual’s risk for advanced AMD. Also, the company launched Sjö, a diagnostic test for the early detection of Sjögren’s syndrome to the national market.

■ AcuFocus announced that the FDA Ophthalmic Devices Advisory Panel determined that the Kamra inlay’s benefits outweigh its risks for presbyopia patients. The FDA will consider this conclusion when determining the benefit-risk of the Pre-Market Approval (PMA) submission for the Kamra inlay.